Rapid screening for safe, responsive immunotherapy treatment
Immune monitoring for patients receiving cancer immunotherapy is vital for understanding the process and efficacy throughout the course of the treatment. Characterizing the immune status for insights into the therapy’s potential is essential, particularly in patients who are receiving novel immune-modulating therapies. Speed and efficiency of immune assays allow for real-time feedback and the ability to be agile in a patient’s treatment regimen.
Enable rapid screening and design
The BioXp™ system’s high-throughput gene synthesis and flexible cloning modalities enable rapid screening and design of novel chimeric antigen receptors (CARs), engineered TCRs, and artificial transcription factors, thus supporting the investigation of different CAR designs to enhance their tumor specificity, or to fine-tune T cell activity. Further, the development of novel gene circuits or CARs to increase effectiveness of CAR-T therapy by engineering T cell mobility or mitigating immunosuppressive cues in the cancer microenvironment can help drive improved efficacy.